Chemotherapy-Induced Cardiomyopathy

American Heart Association. (2000). 2001 heart and stroke statistical update. Dallas, TX: Author.

Criteria Committee of the New York Heart Association. (1994). Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (9th ed.). New York: Little, Brown.

Hunt, S.A., Baker, D.W., Chin, M.H., Cinquegrani, M.P., Feldman, A.M., Francis, G.S., et al. (2001). ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Journal of the American College of Cardiology, 38, 2101-2013.

Jessup, M., & Brozena, S. (2003). Medical progress: Heart failure. New England Journal of Medicine, 348, 2007-2018.

Keefe, D. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95, 1592-1600.

Nousiainen, T., Vanninen, E., Jantunen, E., Remes, J., Kuikka, J., & Hartikainen, J. (2001). Anthracyline-induced cardiomyopathy: Long-term effects on myocardial cell integrity, cardiac adrenergic innervation, and fatty acid uptake. Clinical Physiology, 21, 123-128.

Chien, K.R. (2000). Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity. Seminars in Oncology, 27(Suppl. 11), 9-14.

Ewer, M.S., Gibbs, H.R., Swafford, J., & Benjamin, R.S. (1999). Cardiotoxicity in patients receiving trastuzumab: Primary toxicity, synergistic or sequential stress, or surveillance artifact? Seminars in Oncology, 26, 96-101.

Freidrich, M.J. (2002). Cardiotoxicity concerns prompt data review in breast cancer trial. Journal of the National Cancer Institute, 94, 650-651.

Hunt, S.A., Baker, D.W., Chin, M.H., Cinquegrani, M.P., Feldman, A.M., Francis, G.S., et al. (2001). ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Journal of the American College of Cardiology, 38, 2101-2013.

Keefe, D. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95, 1592-1600.

McKeage, K., & Perry, C.M. (2002). Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs, 62, 209-243.

Seidman, A., Hudis, C., Pierri, M.K., Shak, S., Paton, V., Ashby, M., et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20, 1215-1221.

Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H.P., Bajamonde, A., Fleming, T., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783-792.

Smith, I.E. (2001). Efficacy and safety of Herceptin in women with metastatic breast cancer: Results from pivotal clinical studies. Anticancer Drugs, 12(Suppl. 4), S3-S10.

Sparano, J.A., Brown, D.L., & Wolff, A.C. (2002). Predicting cancer therapy-induced cardiotoxicity: The role of troponins and other markers. Drug Safety, 25, 301-311.